Novo Nordisk cut direct-to-consumer prices for Wegovy and Ozempic to $349 a month for cash-paying patients, while the highest Ozempic dose stays $499. A temporary offer lets new cash payers get the two lowest doses for $199 a month for the first two months, ending March 31. The moves follow deals with the Trump administration, including lower prices paid by the government, Medicare coverage of obesity drugs for certain patients, and discounted medicines on the TrumpRx site launching in January. The administration set starting doses at $350, trending to $245; Eli Lilly also trimmed Zepbound prices on LillyDirect.